Black Diamond Therapeutics, Inc. (BDTX) SEC filings

BDTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 7/30

$1.47−0.05 (-3.29%)

Close on Nov 13, 2026Market cap $84.46MP/E –Yield –

SEC filings

40 of Black Diamond Therapeutics's most recent filings on SEC EDGAR

Document	Form	Period	Filed	Source
Quarterly report	10-Q	Sep 30, 2026	Nov 10, 2026	SEC EDGAR
Current report	8-K	Nov 10, 2026	Nov 10, 2026	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2026	Aug 5, 2026	SEC EDGAR
Current report	8-K	Aug 5, 2026	Aug 5, 2026	SEC EDGAR
Current report	8-K	Jun 26, 2026	Jun 29, 2026	SEC EDGAR
Current report	8-K	May 21, 2026	May 21, 2026	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2026	May 7, 2026	SEC EDGAR
Current report	8-K	May 7, 2026	May 7, 2026	SEC EDGAR
Proxy statement	DEF 14A	Jun 26, 2026	Apr 29, 2026	SEC EDGAR
Annual report	10-K	Dec 31, 2025	Mar 16, 2026	SEC EDGAR
Current report	8-K	Mar 16, 2026	Mar 16, 2026	SEC EDGAR
Current report	8-K	Dec 3, 2025	Dec 3, 2025	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2025	Nov 6, 2025	SEC EDGAR
Current report	8-K	Nov 6, 2025	Nov 6, 2025	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2025	Aug 7, 2025	SEC EDGAR
Current report	8-K	Aug 7, 2025	Aug 7, 2025	SEC EDGAR
Current report	8-K	Jun 12, 2025	Jun 12, 2025	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2025	May 12, 2025	SEC EDGAR
Current report	8-K	May 12, 2025	May 12, 2025	SEC EDGAR
Proxy statement	DEF 14A	Jun 12, 2025	Apr 18, 2025	SEC EDGAR
Current report	8-K	Mar 18, 2025	Mar 19, 2025	SEC EDGAR
Annual report	10-K	Dec 31, 2024	Mar 6, 2025	SEC EDGAR
Current report	8-K	Mar 6, 2025	Mar 6, 2025	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2024	Nov 5, 2024	SEC EDGAR
Current report	8-K	Nov 5, 2024	Nov 5, 2024	SEC EDGAR
Current report	8-K	Oct 7, 2024	Oct 7, 2024	SEC EDGAR
Current report	8-K	Sep 23, 2024	Sep 23, 2024	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2024	Aug 6, 2024	SEC EDGAR
Current report	8-K	Aug 6, 2024	Aug 6, 2024	SEC EDGAR
Current report	8-K	Jun 6, 2024	Jun 6, 2024	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2024	May 9, 2024	SEC EDGAR
Current report	8-K	May 9, 2024	May 9, 2024	SEC EDGAR
Proxy statement	DEF 14A	Jun 6, 2024	Apr 24, 2024	SEC EDGAR
Current report	8-K	Apr 10, 2024	Apr 11, 2024	SEC EDGAR
Annual report	10-K	Dec 31, 2023	Mar 12, 2024	SEC EDGAR
Current report	8-K	Mar 12, 2024	Mar 12, 2024	SEC EDGAR
Current report	8-K	Jan 17, 2024	Jan 18, 2024	SEC EDGAR
Current report	8-K	Jan 4, 2024	Jan 4, 2024	SEC EDGAR
Current report	8-K	Dec 13, 2023	Dec 13, 2023	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2023	Nov 6, 2023	SEC EDGAR

Where these numbers come from

Parsed from the XBRL in Black Diamond Therapeutics's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is BDTX.

Compare: BDTX vs GLUE · BDTX vs KYMR · BDTX vs CHRS · BDTX vs STRO · BDTX vs CCCC

Revenue growth-100.0% · median 7.2%

Company	Revenue	Growth
KYMR	$102.24M	+133.8%
GLUE	$70.33M	-61.3%
CHRS	$53.64M	+44.4%
STRO	$45.11M	-57.3%
CCCC	$32.28M	+7.2%
BDTX	$0	-100.0%

Company

Next earnings (est.): Mar 15, 2027, during market hours
Exchange: Nasdaq
Industry: Biological Products, (No Diagnostic Substances)
Fiscal year ends: December 31
Employees: 21
Held by institutions: 61.0%
Auditor: PricewaterhouseCoopers LLP
SEC CIK: 1701541

Advertisement
300 × 250

See a number that looks wrong?